#China #Shanghai #WuXi Biologics #MSCI ESG Rating #Green CRDMO

WuXi Biologics: Three Years of ESG Excellence

WuXi Biologics (2269.HK), a premier Contract Research, Development, and Manufacturing Organization (CRDMO), recently announced a significant milestone in its commitment to sustainability by earning the prestigious MSCI AAA ESG rating for the third consecutive year. This accolade from Morgan Stanley Capital International (MSCI) distinguishes WuXi Biologics among a select group of companies recognized globally for their exemplary environmental, social, and governance (ESG) practices.

What is MSCI ESG Rating?

The MSCI ESG Ratings evaluate over 17,000 issuers across 999,000 securities worldwide, providing a comprehensive overview of companies' performance with respect to sustainability risks and opportunities. By measuring resilience against industry-specific challenges, these ratings guide investors in assessing the sustainability aspect of their investments.

Strong Leadership in Sustainability

Dr. Chris Chen, the CEO of WuXi Biologics, remarked on this achievement, stating that the recognition affirms their unwavering dedication to sustainable practices. The company positions itself as a leader in Green CRDMO, consistently pushing for excellence in ESG areas such as climate change initiatives, product safety, human capital development, and robust corporate governance.

In alignment with the United Nations Sustainable Development Goals, WuXi Biologics remains actively involved with the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative. Recently, the company unveiled its ambitious near-term and net-zero greenhouse gas emissions-reduction target matrix, which has received endorsement from the Science Based Targets initiative (SBTi).

Awards and Recognition

WuXi Biologics' efforts in sustainability have not gone unnoticed. In addition to the current MSCI AAA rating, the company boasts numerous accolades, including:

• - An EcoVadis Platinum Medal
• - Membership in the Dow Jones Sustainability Indices (DJSI)
• - Inclusion in the CDP Water Security "A List"
• - A- CDP Climate Change leadership-level score, maintained for two consecutive years
• - A negligible-risk rating by Sustainalytics, recognized as a top-rated company in both industry and regional categories for five straight years
• - Selection as a constituent of the FTSE4Good Index Series
• - Listing in the Hang Seng ESG 50 Index
• - Rated as Prime by ISS ESG Corporate Rating

These recognitions showcase WuXi Biologics' zealous approach to integrating sustainable practices within its operational framework.

Commitment to Continuous Improvement

The commitment to sustainability is deeply rooted in WuXi Biologics' corporate strategy, which views ESG excellence as the bedrock for long-term growth. The company remains dedicated to generating shared value by collaborating with stakeholders across its value chain. This effort aims to positively influence social and environmental impacts while ensuring responsible practices are upheld at all levels.

WuXi Biologics continues to innovate in green technology, striving to offer comprehensive end-to-end Green CRDMO solutions to its global partners. By doing so, they not only enhance their operational efficiency but also contribute meaningfully to the well-being of the planet and its inhabitants.

To learn more about WuXi Biologics and its sustainability initiatives, visit www.wuxibiologics.com.